Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts

Annals of the Rheumatic Diseases

Volumn 74, Issue 5, 2015, Pages 806-812

  Van Nies, J A B ^a   Tsonaka, R ^a   Gaujoux Viala, C ^b   Fautrel, B ^c   Van Der Helm Van Mil, A H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; ISOXAZOLE DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYMPTOM; AGED; AREA UNDER THE CURVE; ARTHRITIS, RHEUMATOID; DISEASE COURSE; IMMUNOLOGY; PROPORTIONAL HAZARDS MODEL; TIME TO TREATMENT; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYCHLOROQUINE; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; SULFASALAZINE; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84926434271     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206047     Document Type: Article

References (29)

1. van Nies J.A., Krabben A, Schoones J.W., et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014; 73:861-70.
2. van der Linden MP, le Cessie S, Raza K, et al Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010; 62:3537-46.
3. Anderson JJ, Wells G, Verhoeven A.C., et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22-9.
4. Feldman DE, Bernatsky S, Houde M., et al. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? Rheumatology (Oxford) 2013; 52:452-9.
5. Symmons DP, Jones MA, Scott D.L., et al. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25:1072-7.
6. Nell VP, Machold KP, Eberl G, et al Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:906-14.
7. Lukas C, Combe B, Ravaud P., et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Etude et Suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 2011; 63:1804-11.
8. Raza K. The Michael Mason prize: early rheumatoid arthritis - the window narrows. Rheumatology (Oxford) 2010; 49:406-10.
9. Egsmose C, Lund B, Borg G., et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22:2208-13.
10. Tsakonas E, Fitzgerald AA, Fitzcharles M.A., et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000; 27:623-9.
11. de Rooy D.P., van der Linden MP, Knevel R, et al. Predicting arthritis outcomes - what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50:93-100.
12. Combe B, Benessiano J, Berenbaum F., et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007; 74:440-5.
13. Raza K, Saber TP, Kvien T.K., et al. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 2012; 71:1921-3.
14. Heinzl H, Kaider A, Zlabinger G. Assessing interactions of binary time-dependent covariates with time in cox proportional hazards regression models using cubic spline functions. Stat Med 1996; 15:2589-601.
15. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997; 54:201-8.
16. R Foundation for Statistical Computing VA. R Core Team (2013). R: A language and environment for statistical computing. 2014. Ref Type: Online Source
17. Therneau Tm, Grambsch PM Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
18. Heagerty PJ, Lumley T, Pepe MS Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56:337-44.
19. Emery P. The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol 1997; 24:1436-42.
20. Green M, Marzo-Ortega H, McGonagle D., et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 1999; 42:2184-8.
21. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002; 46:283-5.
22. Wolfe F, Hawley DJ, Cathey MA Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18:1290-7.
23. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21 (5 Suppl 31):S154-7.
24. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003; 48:1771-4.
25. Amjadi S, Khanna D, Park G.S., et al. Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol 2004; 31:1686-92.
26. Smolen JS, Landewe R, Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492-509.
27. Landewe RB, Boers M, Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46:347-56.
28. Mottonen T, Hannonen P, Korpela M., et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46:894-8.
29. Luqmani R, Hennell S, Estrach C., et al. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 2006; 45:1167-9.